ALBERTDAVDBSEAlbert David Ltd-$HighNeutral
Announced Tue, 12 May · 19:04 IST

Re-appointment of Internal Auditors for the F.Y. 2026-27

Ceo Appointed ExternalManagement Changes View source PDF

ALBERTDAVD · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-10.5%1-day move
₹790.00
prior close
₹730.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-1.9-1.9-2.3-2.1-10.5-8.6-10.1-9.2-10.4-10.6-8.8-8.3-11.2
Up moveDown movePending
AI summary

Albert David Ltd's board meeting on May 12, 2026 approved several key items. Mr. Amit Mahla was appointed as CEO (effective same day), succeeding Mr. Umesh Manohar Kunte who resigned as Managing Director & CEO effective December 18, 2025. The company reported audited FY2026 results showing revenue of Rs 33,359.81 Lacs but a net loss of Rs 149.47 Lacs, a sharp decline from FY2025 profit of Rs 2,522.77 Lacs. The Q4 loss was Rs 2,143.44 Lacs. The board recommended a final dividend of Rs 5 per share (50% on Rs 10 face value) for FY2026, subject to shareholder approval at the 87th AGM scheduled for August 6, 2026. PwC Services LLP was re-appointed as Internal Auditors and M/s. S. Gupta & Co. as Cost Auditors for F.Y. 2026-27.

Likely market impact

The company saw a significant turnaround from profit to loss in FY2026, requiring close monitoring. The appointment of an experienced pharmaceutical executive as CEO may provide strategic direction. The continuation of the dividend signals management confidence despite losses.